Jolijn V. D.
- Country
- The Netherlands
- Department
- Neurology
Research Overview
Data & Insights
Has run more than one trial at 0 of 21 partner sites.
Specializations
Cardiovascular & Lipid Management
Focuses on prevention and treatment of atherosclerotic cardiovascular disease, acute coronary events, and dyslipidaemia.
- Acute coronary syndrome
- Atherosclerotic cardiovascular disease
- Elevated lipoprotein(a)
- Hypertriglyceridemia
- Primary prevention of ASCVD
Investigates novel RNA‑based and monoclonal approaches to lower LDL‑C and Lp(a).
Heart Failure & Pulmonary Hypertension
Dedicated to chronic heart failure phenotypes, including preserved ejection fraction and associated pulmonary hypertension.
- Heart failure with preserved ejection fraction
- Heart failure with mildly reduced ejection fraction
- Pulmonary hypertension due to left heart disease
- Reduced left ventricular ejection fraction post‑myocardial infarction
Evaluates targeted peptide therapeutics and combination regimens to improve ventricular function.
Oncology – Solid Tumors & Lymphoma
Engages in clinical studies of advanced solid tumours and lymphoid malignancies, emphasizing targeted and immunotherapeutic strategies.
- Advanced non‑small cell lung cancer
- Diffuse large B‑cell lymphoma
- Triple‑negative breast cancer
- HER2‑positive esophageal adenocarcinoma
- Metastatic colorectal cancer
Assesses biomarker‑driven treatment adaptation and combination chemotherapy.
Neurology & Autoimmune Disorders
Applies neurological expertise to inflammatory and autoimmune conditions, including demyelinating disease.
- Multiple sclerosis
- Chronic spontaneous urticaria
- Severe asthma with eosinophilic phenotype
- Steroid‑sensitive idiopathic nephrotic syndrome
- Unexplained subfertility
Integrates biologic agents targeting cytokine pathways.
Renal & Metabolic Kidney Disease
Targets renal outcomes linked to cardiovascular risk and metabolic dysfunction.
- Kidney failure
- Chronic kidney disease with eGFR ≤25
- Diabetes‑related dyslipidaemia
- Obesity‑related cardiovascular risk
Studies SGLT2 inhibition and lipid‑lowering combinations to reduce renal events.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.